PAPA (Papa Medical) Debt-to-EBITDA : 0.45 (As of Mar. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Papa Medical Debt-to-EBITDA?

Papa Medical PAPA Debt-to-EBITDA is 0.45 as of Mar. 2025.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Papa Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $1.25 Mil. Papa Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was $1.34 Mil. Papa Medical's annualized EBITDA for the quarter that ended in Mar. 2025 was $5.71 Mil. Papa Medical's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 was 0.45.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Papa Medical's Debt-to-EBITDA or its related term are showing as below:

PAPA's Debt-to-EBITDA is not ranked *
in the Tobacco Products industry.
Industry Median: 1.37
* Ranked among companies with meaningful Debt-to-EBITDA only.

Papa Medical  (NAS:PAPA) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Papa Medical Debt-to-EBITDA Related Terms

Papa Medical Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Papa Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Papa Medical Debt-to-EBITDA Chart

Papa Medical Annual Data
Trend Dec22 Dec23 Dec24
Debt-to-EBITDA
0.19 0.68 1.15

Papa Medical Quarterly Data
Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only 0.00 1.15 0.80 3.49 0.45

PAPA vs : Debt-to-EBITDA Comparison

For the Tobacco subindustry, Papa Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Papa Medical Debt-to-EBITDA vs Tobacco Products Industry

For the Tobacco Products industry and Consumer Defensive sector, Papa Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Papa Medical's Debt-to-EBITDA falls into.


Papa Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Papa Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.041 + 1.624) / 2.322
=1.15

Papa Medical's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.252 + 1.34) / 5.708
=0.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2025) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of 0.45 mean?
Papa Medical (PAPA) has a Debt-to-EBITDA of 0.45 as of Mar. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Papa Medical.
Is Papa Medical's Debt-to-EBITDA too high?
Papa Medical's current Debt-to-EBITDA is 0.45. The Tobacco Products industry median Debt-to-EBITDA is 1.37. Papa Medical's value of 0.45 is 67.2% below this industry median.
How does Papa Medical's Debt-to-EBITDA compare to ?
Papa Medical's Debt-to-EBITDA of 0.45 can be compared against companies in the Tobacco Products industry. The industry median Debt-to-EBITDA is 1.37. Papa Medical's value of 0.45 is 67.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Tobacco Products company?
The median Debt-to-EBITDA among Tobacco Products companies is 1.37, based on 35 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Papa Medical's current Debt-to-EBITDA of 0.45 is 67.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Papa Medical. For the Tobacco Products industry, the median Debt-to-EBITDA is 1.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Papa Medical's current Debt-to-EBITDA is 0.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Papa Medical stock overvalued right now?
Papa Medical (PAPA) has a current Debt-to-EBITDA of 0.45. The current Debt-to-EBITDA is 0.45 and 67.2% below the Tobacco Products industry median of 1.37. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Papa Medical (PAPA), the current Debt-to-EBITDA is 0.45 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Papa Medical Business Description

Comparable Companies
Address 202 North California Ave, City of Industry, CA, USA, 91744
Papa Medical Inc is the first end-to-end cannabis dosing solution provider in the U.S. that possesses the medical atomization or nebulizing background and sells nebulizers. The company deeply engages in key activities in the cannabis and consuming E-vapors industry, from research and development, formulation design, e-liquid production, and e-liquid filling to e-liquid co-packing services. It is engaged in the research and development, design, commercialization, sales, marketing and distribution of branded e-cigarettes and cannabis E-vapors.